1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
Immunosuppressants Global Market Report 2021: COVID-19 Growth And Change To 2030

Immunosuppressants Global Market Report 2021: COVID-19 Growth And Change To 2030

  • September 2021
  • 175 pages
  • ID: 6151688
  • Format: PDF
  • The Business Research Company


Table of Contents

Major players in the immunosuppressant market are Astellas Pharma, GlaxoSmithKline, Bristol Myers Squibb, Johnson & Johnson, Intas Pharmaceuticals Ltd., Mylan Laboratories Inc, Pfizer, Novartis, Novartis AG, and Sanofi S.A.

The global immunosuppressants market is expected to grow from $15.04 billion in 2020 to $16.5 billion in 2021 at a compound annual growth rate (CAGR) of 9.7%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $25.33 billion in 2025 at a CAGR of 11%.

The immunosuppressant market consists of sales of immunosuppressants or anti-rejection drugs generated by companies manufacturing immunosuppressant drugs.Immunosuppressants are medicinal substances that prevent or inhibit activity in the immune system.

Immunosuppressive drugs are mainly used in organ transplantation procedures and also in the treatment of certain autoimmune diseases such as rheumatoid arthritis, psoriasis, multiple sclerosis, and others.

The immunosuppressants market covered in this report is segmented by drug class into corticosteroids, monoclonal antibodies (MABs), calcineurin inhibitors, mTOR inhibitors, anti-proliferative agents, others. It is also segmented by indication into organ transplantation, autoimmune disorders, non-autoimmune inflammatory diseases and by distribution channel into hospital pharmacies, retail pharmacies, online pharmacies.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Stringent government regulations are expected to hamper the growth of the market.Regulators such as the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) maintain public safety for food and drugs through a stringent regulatory drug approval process.

For an immunosuppressant drug to be approved by the regulatory authorities, the sponsor must provide satisfactory evidence regarding the safety and efficacy of a drug in a patient with a defined clinical condition.Sponsors should submit to the Center for Drug Evaluation and Research (CDER) any information on the immunotoxicology evaluation of drugs whenever such information becomes available, for review.

Many guidelines have also been adopted by the EU including those providing general guidance, more specific guidance on quality issues, and non-clinical and clinical aspects. Therefore, the stringent regulatory and approval process on immunosuppressant drugs are projected to hamper the overall growth of the immunosuppressants market.

In 2019, AbbVie, an American publicly-traded biopharmaceutical company, acquired Allergan for $63 billion.The transaction significantly expanded and diversified AbbVie’s revenue base and existing leadership position in immunology with humira and recently launched skyrizi and rinvoq, and hematologic oncology with imbruvica and venclexta.

Allergan provides new growth opportunities in neuroscience, with Botox therapeutics, Vraylar, and Ubrelvy and a global aesthetics business, with leading brands including Botox and Juvéderm. Allergan is an Irish-domiciled pharmaceutical company that develops, manufactures, and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology.

The surge in organ transplant procedures such as kidney transplant and liver transplant due to the rise in incidences of organ failure is the major factor driving the immunosuppressant market growth. According to the United Network for Organ Sharing (UNOS), 39,718 organ transplants were performed in 2019 in the United States, and as of March 2020, there are more than 112,000 candidates on the U.S. national transplant waiting list, waiting for an organ transplant. According to the Global Liver Institute’s 2019 report, there are 13,192 liver patients in the U.S. waiting for a lifesaving transplant. The increasing number of cases of organ transplants and organ failure incidences in patients are, therefore, expected to drive the market growth.

The phenotypic personalized medicine or PPM or a hybrid of artificial intelligence and physician intervention is a new approach to overcome the issues with immunosuppressants.For instance, Tacrolimus is the most widely used immunosuppressant for patients who are undergoing organ transplantation.

When the patient is in the hospital, Tacrolimus immunosuppressant levels must be checked regularly and changed frequently.PPM approach that is based on a computational platform is used to overcome this concern.

The inputs from the computational platform-based PPM approach includes the past response of the patient to the dose of the drug and other drugs that are being taken, and current data on liver and kidney.Using PPM, the physician can identify the optimal drug and dose combination from various possibilities.

Therefore, it is believed that artificial intelligence is leading the way to not only more personalized and effective drug dosing but also enhancing physicians’ decision-making capabilities by providing clinical data rather than predicted responses.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Immunosuppressant Drugs Market Research Report by Function, by Route of Administration, by Drug Class, by End User, by State - United States Forecast to 2026 - Cumulative Impact of COVID-19

  • $ 4949
  • October 2021
  • 198 pages

Immunosuppressant Drugs Market Research Report by Function (Autoimmune Diseases and Organ Transplant), by Route of Administration (Intravenous and Oral), by Drug Class, by End User, by State (California, ...

  • United States
  • Transplantation
  • Industry analysis


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on